Inhibition of Tripeptidyl Peptidase Ii by the Tripeptide Aaf-CMK Impairs Dendritic Cell Maturation and Function

Berges, Carsten; Naujokat, Cord; Tinapp, Sarah; Wieczorek, Hubert; Sadeghi, Mehrnoosh; Opelz, Gerhard; Daniel, Volker

doi:10.1097/00007890-200407271-01634

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To investigate whether the EboGPΔM fusion protein could mediate cell entry, we used equal amounts of EboGPΔM, EboGPΔM-V3 or EboGPΔM-V3-V5 pseudotyped Gluc + VLPs and HIVEnv(T/M)-GLuc + VLPs (adjusted by HIV Gagp24 levels) to infect TZMB1 cells (HeLa cells expressing CD4+/CXCR4 with integrated HIV-LTR-luciferase), a CD4+ T lymphoid cell line (C8166 T cells), Vero E6 cells, and a human monocytic cell line (THP1 cells) (7). In parallel, we used a VLP without any viral envelope glycoprotein (Env --Gluc+) as a negative control.…”

Section: Investigation Of Cell Entry Mediated By Each Ebogpδm Fusion Protein In Various Cell Lines Primary Macrophages and Dendritic Cellmentioning

confidence: 99%

Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1

Wang

Azizi

et al. 2021

J Virol

View full text Add to dashboard Cite

The development of efficient vaccine approaches against HIV infection remains challenging in the vaccine field. We herein developed an Ebola virus envelope glycoprotein (EboGP)-based chimeric fusion protein system and demonstrated that replacement of the mucin-like domain (MLD) of EboGP with HIV C2-V3-C3 (134 aa) or C2-V3-C3-V4-C4-V5-C5 (243 aa) polypeptides (EbGPΔM-V3 and EbGPΔM-V3-V5, respectively) still maintained the efficiency of EboGP-mediated viral entry into human macrophages and dendritic cells (DCs). Animal studies using mice revealed that immunization with virus-like particles (VLPs) containing the above chimeric proteins, especially EbGPΔM-V3, induced significantly more potent anti-HIV antibodies than HIV gp120 alone in mouse serum and vaginal fluid. Moreover, the splenocytes isolated from mice that immunized with VLPs containing EbGPΔM-V3 produced significantly higher levels of IFN-γ, IL-2, IL-4, IL-5 and MIP-1α. Additionally, we demonstrated that co-expression of EbGPΔM-V3 and the HIV Env glycoprotein in a recombinant vesicular stomatitis virus (rVSV) vector elicited robust anti-HIV antibodies that may have specifically recognized outside or inside the C2-V3-C3 region of HIV-1 gp120 and cross-reacted with the gp120 from different HIV strains. Thus, this study has demonstrated the great potential of this DC-targeting vaccine platform as a new vaccine approach for improving immunogen delivery and increasing vaccine efficacy. Importance Currently, there are more than 38.5 million reported cases of HIV globally. To date, there is no approved vaccine for HIV-1 infection. Thus, the development of an effective vaccine against HIV infection remains a global priority. This study revealed the efficacy of a novel Dendritic Cells (DC)-targeted vaccination approach against HIV-1. The results have clearly shown that the immunization of mice with virus-like particles (VLPs) and VSVs containing HIV Env and a fusion protein comprised of a DC-targeting domain of Ebola GP with HIV C2-V3-C3 polypeptides (EbGPΔM-V3) could induce robust immune responses against HIV-1 Env and/or Gag in sera and vaginal mucosa. These findings have provided a proof of concept of this novel and efficient DC-targeting vaccine approach in delivering various antigenic polypeptides of HIV-1 and/or other emergent infections to the host antigen-presenting cells to prevent HIV and other viral infections.

show abstract

Section: Investigation Of Cell Entry Mediated By Each Ebogpδm Fusion Protein In Various Cell Lines Primary Macrophages and Dendritic Cellmentioning

confidence: 99%

Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1

Wang

Azizi

et al. 2021

J Virol

View full text Add to dashboard Cite

show abstract

Inhibition of Tripeptidyl Peptidase Ii by the Tripeptide Aaf-CMK Impairs Dendritic Cell Maturation and Function

Cited by 1 publication

References 0 publications

Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1

Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1

Contact Info

Product

Resources

About